REG - Adv Medical Solutns. - Appointment of Adviser

Advanced Medical SolutionsAnnouncement

04/11/2021 07:00

RNS Number : 2813R
  
Advanced Medical Solutions Grp PLC
  
04 November 2021
  
 

04 November 2021
 
Advanced Medical Solutions Group plc
("AMS" or the "Group")
Appointment of Adviser
Winsford, UK: Advanced Medical Solutions plc (AIM: AMS), the surgical and advanced wound care specialist company, today announces the appointment of HSBC Bank plc ("HSBC") as its Joint Broker and Joint Financial Adviser, with immediate effect. Investec Bank plc will continue to act as Nominated Adviser, Joint Broker and Joint Financial Adviser to the Company.
 
- End -
 
For further information, please contact:



Advanced Medical Solutions Group plc


Tel: +44 (0) 1606 545508




Chris Meredith, Chief Executive Officer
Eddie Johnson, Chief Financial Officer
Michael King, Investor Relations Manager


















Consilium Strategic Communications


Tel: +44 (0) 20 3709 5700




Mary-Jane Elliott / Matthew Neal / Matthew Cole


















Investec Bank plc - Nominated Adviser,  Joint Broker and Joint Financial Adviser


Tel: +44 (0) 20 7597 5970




Daniel Adams / Gary Clarence








 
HSBC Bank plc - Joint Broker and Joint Financial Adviser


 
Tel: 44 (0)20 7991 8888




Sam McLennan / Joe Weaving







 
About Advanced Medical Solutions Group plc 
 
AMS is a world-leading independent developer and manufacturer of innovative and technologically advanced products for the global surgical and woundcare markets, focused on quality outcomes for patients and value for payers. AMS has a wide range of surgical products including tissue adhesives, sutures, haemostats, internal fixation devices and internal sealants, which it markets under its brands LiquiBand®, RESORBA®, LiquiBandFix8® and Seal-G®. AMS also supplies wound care dressings such as silver alginates, alginates and foams through its ActivHeal® brand as well as under white label. In 2019, the Group made two acquisitions: Sealantis, an Israeli medical device company with a patent-protected sealant technology platform; and Biomatlante, an established developer and manufacturer of innovative surgical biomaterial technologies based in France. In 2020, the Group acquired Raleigh Adhesive Coatings, a leading coater and converter of materials predominately for woundcare and bio-diagnostics products based in the UK.
AMS's products, manufactured in the UK, Germany, France, the Netherlands, the Czech Republic and Israel, are sold globally via a network of multinational or regional partners and distributors, as well as via AMS's own direct sales forces in the UK, Germany, the Czech Republic and Russia. The Group has R&D innovation hubs in the UK, Germany, France and Israel. Established in 1991, the Group has more than 700 employees. For more information, please see www.admedsol.com.
 
 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
  END
 
 
APPFSFFUDEFSELF